NEW YORK — Biotech firm Avacta said on Thursday that it has entered into a collaboration agreement with Bruker to evaluate a MALDI mass spectrometry-based test for SARS-CoV-2 using the Avacta's Affirmer affinity reagents.
The companies will determine the test's suitability as an in vitro diagnostic for SARS-CoV-2 to be run on Bruker's MALDI-TOF instruments in the UK and Europe.